# Nuclide record nsclc (indication). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/indications/nsclc/>
  a schema:MedicalCondition ;
  nuclide:kind "indication" ;
  schema:identifier "nsclc" ;
  schema:name "Non-small cell lung cancer"@en ;
  schema:alternateName "NSCLC"@en, "lung cancer"@en, "lung adenocarcinoma"@en, "lung squamous cell carcinoma"@en, "large cell lung carcinoma"@en ;
  schema:description "The cancer that kills more people than any other, and the reason most PET scanners are busy. Most cases are found once the disease has already spread, and a scan with radioactive sugar is what decides who can still be cured by surgery."@en ;
  schema:url <https://nuclide.cc/indications/nsclc/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Non-small-cell_lung_cancer> ;
  owl:sameAs <http://www.wikidata.org/entity/Q3658562> ;
  schema:citation <https://www.cancer.gov/types/lung/hp/non-small-cell-lung-treatment-pdq>, <https://seer.cancer.gov/statfacts/html/lungb.html>, <https://gco.iarc.fr/media/globocan/factsheets/cancers/15-trachea-bronchus-and-lung-fact-sheet.pdf>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1450>, <https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/lung-cancer-screening>, <https://pmc.ncbi.nlm.nih.gov/articles/PMC12165876/>, <https://doi.org/10.1007/s00259-007-0449-7>, <https://doi.org/10.2967/jnumed.123.266806> ;
  nuclide:tag "lung", "diagnostic", "staging" ;
  nuclide:related <https://nuclide.cc/indications/sclc/>, <https://nuclide.cc/indications/lung-net/>, <https://nuclide.cc/isotopes/f-18/>, <https://nuclide.cc/isotopes/tc-99m/>, <https://nuclide.cc/isotopes/ga-68/>, <https://nuclide.cc/drugs/pb-212-psv359/>, <https://nuclide.cc/indications/pulmonary-embolism-vq/>, <https://nuclide.cc/technologies/split-function-lung-perfusion/> ;
  nuclide:indications <https://nuclide.cc/indications/sclc/>, <https://nuclide.cc/indications/lung-net/> ;
  nuclide:technologies <https://nuclide.cc/technologies/fdg-pet/>, <https://nuclide.cc/technologies/pet-ct/>, <https://nuclide.cc/technologies/ct/>, <https://nuclide.cc/technologies/spect-ct/>, <https://nuclide.cc/technologies/fapi-pet/>, <https://nuclide.cc/technologies/radiomics/>, <https://nuclide.cc/technologies/split-function-lung-perfusion/> ;
  nuclide:targets <https://nuclide.cc/targets/glut-hexokinase/>, <https://nuclide.cc/targets/fap/>, <https://nuclide.cc/targets/integrin-avb3/> ;
  nuclide:drugs <https://nuclide.cc/drugs/fludeoxyglucose-f18/>, <https://nuclide.cc/drugs/pexiretide-tc99m/>, <https://nuclide.cc/drugs/ga-68-fapi-46/>, <https://nuclide.cc/drugs/f-18-fluorothymidine/>, <https://nuclide.cc/drugs/tc-99m-mdp/>, <https://nuclide.cc/drugs/tc-99m-maa/> ;
  nuclide:trials <https://nuclide.cc/trials/nct06107374/>, <https://nuclide.cc/trials/nct07276789/> ;
  nuclide:pipeline <https://nuclide.cc/drugs/pexiretide-tc99m/>, <https://nuclide.cc/drugs/ga-68-fapi-46/>, <https://nuclide.cc/technologies/fapi-pet/>, <https://nuclide.cc/drugs/f-18-fluorothymidine/>, <https://nuclide.cc/drugs/pb-212-psv359/>, <https://nuclide.cc/trials/nct06107374/>, <https://nuclide.cc/trials/nct07276789/> ;
  nuclide:standardOfCare <https://nuclide.cc/technologies/ct/>, <https://nuclide.cc/technologies/ct/>, <https://nuclide.cc/technologies/fdg-pet/>, <https://nuclide.cc/technologies/pet-ct/>, <https://nuclide.cc/drugs/fludeoxyglucose-f18/>, <https://nuclide.cc/technologies/fdg-pet/>, <https://nuclide.cc/technologies/pet-ct/>, <https://nuclide.cc/drugs/tc-99m-mdp/>, <https://nuclide.cc/technologies/ct/> .